Vorinostat is genotoxic and epigenotoxic in the mouse bone marrow cells at the human equivalent doses

Toxicology
Sabry M AttiaSaleh A Bakheet

Abstract

Vorinostat was approved as the first histone deacetylase inhibitor for the management of cutaneous T cell lymphoma. However, it's in vivo genetic and epigenetic effects on non-cancerous cells remain poorly understood. As genetic and epigenetic changes play a critical role in the pathogenesis of carcinogenesis, we investigated whether vorinostat induces genetic and epigenetic alterations in mouse bone marrow cells. Bone marrow cells were isolated 24 h following the last oral administration of vorinostat at the doses of 25, 50, or 100 mg/kg/day for five days (approximately equal to the recommended human doses). The cells were then used to assess clastogenicity and aneugenicity by the micronucleus test complemented by fluorescence in situ hybridization assay; DNA strand breaks, oxidative DNA strand breaks, and DNA methylation by the modified comet assay; apoptosis by annexin V/PI staining analysis and the occurrence of the hypodiploid DNA content; and DNA damage/repair gene expression by polymerase chain reaction (PCR) Array. The expression of the mRNA transcripts were also confirmed by real-time PCR and western blot analysis. Vorinostat caused structural chromosomal damage, numerical chromosomal abnormalities, DNA strand breaks, ...Continue Reading

References

May 24, 2005·Cell Cycle·Alessandra InsingaPier Giuseppe Pelicci
Aug 29, 2007·Radiation Research·Yin ZhangMira Jung
Jul 19, 2008·Cancer Letters·Grégory Eot-HoullierChristian Jaulin
Jan 20, 2009·Environmental and Molecular Mutagenesis·Sabry M AttiaOthman A Al-Shabanah
Nov 12, 2009·International Journal of Toxicology·Janet S KerrPaul A Andrews
Feb 17, 2010·Analytical Biochemistry·Johannes F WentzelPieter J Pretorius
May 19, 2010·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Shannon M KavanaughJill M Kolesar
Jun 12, 2010·Current Topics in Medicinal Chemistry·Sandra C MwakwariAdegboyega K Oyelere
Jul 17, 2010·Journal of the National Cancer Institute·Debra L FriedmanJoseph P Neglia
Aug 4, 2010·Proceedings of the National Academy of Sciences of the United States of America·J-H LeePaul A Marks
Nov 23, 2010·Journal of Applied Toxicology : JAT·Fernanda PículoEdson Luis Maistro
Dec 25, 2012·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Amaya AzquetaAndrew R Collins
Feb 13, 2013·Journal of Applied Toxicology : JAT·Sabry M AttiaSaleh A Bakheet
Jun 14, 2013·Cytotechnology·Karem H AlzoubiMajed M Masadeh
Jul 23, 2013·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Sabry M AttiaSaleh A Bakheet
Dec 18, 2013·Seminars in Oncology·Smita Bhatia
Apr 18, 2014·North American Journal of Medical Sciences·Zhi-Qiang LiuPing-Chang Yang
Apr 22, 2015·Expert Opinion on Drug Discovery·Clemens ZwergelAntonello Mai
Aug 20, 2015·Indian Journal of Dermatology·Aditya Kumar Bubna
Dec 10, 2015·Cancer Chemotherapy and Pharmacology·S M AttiaS A Bakheet
Apr 9, 2016·Journal of Basic and Clinical Pharmacy·Anroop B Nair, Shery Jacob
Aug 10, 2016·Scientific Reports·Vivek NandakumarDeirdre R Meldrum
Oct 14, 2016·Genes and Environment : the Official Journal of the Japanese Environmental Mutagen Society·Makoto Hayashi
Oct 25, 2016·Current Pharmaceutical Design·Dimitry A ChistiakovYuri V Bobryshev

❮ Previous
Next ❯

Citations

Jul 27, 2021·Frontiers in Molecular Biosciences·Alejandra FernandezAmila Suraweera

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Related Papers

Nature Reviews. Drug Discovery
Steven GrantPeter Kirkpatrick
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Eric H RubinMarian Iwamoto
Cancer Chemotherapy and Pharmacology
Marian IwamotoJohn A Wagner
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
Wenwen DaiYouxin Li
© 2022 Meta ULC. All rights reserved